For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Varenicline - Independent medicine & health information for consumers & professionals Varenicline medicine information
(VA-ren-i-kleen)
Latest independent drug information about the active ingredient varenicline and treatments, written and reviewed by experts in Australia.
Varenicline is the active ingredient in the medicine brand Champix.
| Filter by audience: | |
|---|---|
| All | |
| Consumer | |
| Health professional | |
| Researchers & evaluators | |
| Members & stakeholders | |
| Other | |
| Title | Description | Type | Audience  |
Date* |
|---|---|---|---|---|
| Varenicline (Champix) for smoking cessation | Review of varenicline (Champix) for smoking cessation, including adverse effects, treatment efficacy, and drug interactions. | Professional publication - NPS RADAR - Review | Health Professionals | 2011-08-01 00:00:00 |
| Champix | Consumer information from the manufacturer about the use of Champix (varenicline tartrate). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2010-09-10 00:00:00 |
| Clinical audit: Management of stable COPD and smoking cessation | How are you managing your patients with stable chronic obstructive pulmonary disease who are current smokers? Review 10 patients | Professional activity - Clinical audit | Health Professionals | 2010-05-01 00:00:00 |
| Varenicline (Champix) safety update: serious neuropsychiatric and dermatological adverse events | Safety update regarding serious neuropsychiatric and dermatological adverse events associated with varenicline (Champix) | Professional publication - NPS RADAR - Brief item | Health Professionals | 2009-12-01 00:00:00 |
| Varenicline (Champix) — new PBS listing for extra 12 weeks of therapy | Authority PBS listing for a further 12 weeks of varenicline (Champix) for smoking cessation from 1 February 2011. | Professional publication - NPS RADAR - Brief item | Health Professionals | 2011-02-01 00:00:00 |
| Quit smoking | Outlines quit smoking strategies and role of nicotine replacement and Champix. Discusses COPD (chronic obstructive pulmonary disease) and its diagnosis. | Professional publication - NPS News | Health Professionals | 2010-04-01 00:00:00 |
| Varenicline (Champix) for quitting smoking | Find out what varenicline does, its side effects, and how it compares with other medicines for quitting. Find out about ways to quit without medicines too. | Consumer publication - Medicine Update | Consumers | 2011-08-02 00:00:00 |
| Side effects warning about varenicline (Champix) | The National Prescribing Service Limited (NPS) advises people taking the quit-smoking drug varenicline (marketed in Australia as Champix) to speak to their GP or pharmacist or contact Medicines Line if they are concerned about possible side effects. | Media release | Others | 2008-12-04 00:00:00 |
| Will power and support are key to quitting | National Prescribing Service Limited (NPS) advises people wishing to take the new drug varenicline (Champix) to help them quit smoking, to be aware of the possible side effects and to discuss any concerns they have with their doctor or pharmacist | Media release | Others | 2008-01-04 00:00:00 |
| Monitor and support patients on varenicline | Monitor and support patients on varenicline | Media release | Others | 2008-01-07 00:00:00 |
| Quit smoking medicine: new study notes more side effects | National Prescribing Service (NPS) advises people with questions about the quit-smoking drug varenicline (Champix) to contact their doctor or pharmacist for advice due to concerns about potential adverse events. | Media release | Others | 2008-05-22 00:00:00 |
| Keep an eye on quit-smoking patients using varenicline | NPS urges health professionals to monitor patients using varenicline (used by quit smoking patients) for any behaviour and/or mood changes or any unusual symptoms or events that occur while taking the medicine. | Media release | Others | 2008-05-22 00:00:00 |
| New information on Varenicline (Champix) inconclusive: NPS (health professionals) | Uncertainty remains despite new research published this month linking a smoking-cessation medicine to an increased risk of heart attacks, according to NPS | Media release | Others | 2011-07-20 19:00:00 |
| New information on Varenicline (Champix) inconclusive: NPS (for consumers) | New research linking an anti-smoking medicine to an increased risk of heart attacks remains uncertain. Anyone with concerns about taking the medicine should talk to their health professional or seek more information, according to NPS MedicineWise | Media release | Others | 2011-07-20 19:00:00 |
| Which side effects matter? A smoker’s story | Read how a smoker decided which side effects were important to them. | Consumer resource - Story | Consumers | 2011-01-24 00:00:00 |
Information on this website is published by NPS — an independent, evidence based, not-for-profit organisation funded by the Australian Government Department of Health and Ageing.
NPS develops its information under the guidance of experts in their field, editorial panels, expert reviewers and consumers. Find out more about how we develop our content.
Date published: 2010-12-17 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
